Reports Q1 revenue $696,000, consensus $352,830. “We are entering an important time for EyePoint (EYPT) and the retina community with Phase 3 topline data for DURAVYU in wet AMD expected beginning mid-year with LUGANO topline data and the identical LUCIA trial data readout to follow,” said Jay S. Duker, President and Chief Executive Officer of EyePoint. “In parallel, enrollment in our Phase 3 DME program is meeting our ambitious timelines with full enrollment expected in the third quarter of 2026, positioning DURAVYU for pivotal readouts in the two largest multi-billion-dollar retina markets.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EYPT:
- EYPT Upcoming Earnings Report: What to Expect?
- Insiders Dump Shares in Global-e, EyePoint, Immunovant, Nerdy, Argan
- EyePoint Highlights DURAVYU Phase 3 Progress and Cash Runway
- EyePoint Sues Ocular Therapeutix Over Alleged Defamation
- EyePoint’s COMO Phase 3 Trial Puts Long-Acting DME Strategy in Focus